As of August 20, 2026, J&J’s talc settlement strategy has shifted. In 2025, a bankruptcy judge rejected the company’s third attempt to resolve ovarian cancer claims through a subsidiary bankruptcy filing, finding the claimant voting process flawed. After a July 22, 2026 court ruling cast doubt on plaintiffs’ ability to prove their cancer was specifically caused by J&J’s talc, the company pivoted strategy: on July 27, 2026, J&J announced a $5.5 billion settlement negotiated directly with plaintiffs’ law firms, outside of bankruptcy court. The deal covers roughly 76,000 pending ovarian cancer claims, representing about 99.75% of remaining U.S. talc litigation, and would pay claims within about 18 months instead of over decades. It is not yet final — it only takes effect if firms representing at least 95% of eligible claimants agree to participate. J&J expects to make its first payment, capped at $3 billion, in 2027. The deal does not cover mesothelioma claims, about 95% of which J&J says it has already resolved separately.
Last updated: August 2026
Johnson & Johnson faces thousands of lawsuits in 2026 over talc products, prescription drugs, and medical devices that allegedly caused serious harm. The company has set aside billions in settlement funds, but the bankruptcy process and claim filing rules have changed.
If you used J&J Baby Powder, took Risperdal or Invokana, or received a defective medical implant, you might qualify for compensation. The amounts vary widely based on your injury type and proof of use.
This guide breaks down every active J&J lawsuit in 2026. You’ll learn exact settlement amounts, filing deadlines, eligibility requirements, and how to submit your claim.
Over 60,000 talc-related claims alone are pending as of early 2026. That number doesn’t include pharmaceutical and device lawsuits still moving through courts.
Johnson and Johnson Lawsuit
The Johnson and Johnson lawsuit refers to multiple legal actions against the healthcare giant for products that allegedly caused cancer, organ damage, and other serious injuries.
These cases span decades but intensified after 2018 when juries began awarding massive verdicts to plaintiffs. The company denies wrongdoing but has allocated settlement funds exceeding $10 billion across various product lines.
Three main categories dominate the litigation landscape. Talc products top the list with claims linking Baby Powder and Shower to Shower to ovarian cancer and mesothelioma. Pharmaceutical lawsuits target drugs like Risperdal, Invokana, and Xarelto for severe side effects. Medical device claims involve hip implants, surgical mesh, and other products that allegedly failed or caused injuries.
| Lawsuit Category | Estimated Active Claims | Settlement Fund Size |
|---|---|---|
| Talc Products | 60,000+ | $8.9 billion |
| Pharmaceuticals | 25,000+ | $2.1 billion |
| Medical Devices | 15,000+ | $1.5 billion |
The company used a controversial bankruptcy strategy through a subsidiary called LTL Management to handle talc claims. This move paused lawsuits but sparked legal battles over whether a profitable corporation can use bankruptcy to limit liability.
Courts initially rejected the bankruptcy twice. However, a revised settlement proposal in late 2025 gained traction with claimant support, leading to the 2026 framework now in place.
Johnson and Johnson Class Action Lawsuit
Johnson and Johnson class action lawsuits allow groups of people harmed by the same product to combine their claims into one case.
Not all J&J litigation qualifies as class action. Many talc cancer cases proceed as individual lawsuits or mass torts where each plaintiff maintains a separate claim but shares discovery and legal resources.
True class actions exist for certain pharmaceutical and consumer product issues. A 2024 class action in California covers customers who bought J&J sunscreen products containing benzene. Another certified class in New York addresses Risperdal marketing practices.
The difference matters for settlement distribution. Class actions typically divide funds among all members based on a formula. Individual lawsuits allow personalized compensation based on specific injuries and damages.
Most talc cancer claims in 2026 operate under mass tort procedures rather than class action rules. This means your potential payout depends on your unique medical history, not a standardized class member payment.
Some claimants prefer class actions for simplicity. Others choose individual representation to maximize compensation. Your choice depends on injury severity and strength of evidence.
Key Takeaway: Not all J&J lawsuits are class actions; most talc cases are individual mass tort claims with personalized settlement amounts.
J&J Bankruptcy Settlement Update
J&J’s bankruptcy settlement update for 2026 centers on the third attempt to resolve talc claims through LTL Management’s Chapter 11 filing.
The company proposed an $8.9 billion settlement trust in October 2025 after previous bankruptcy attempts failed in 2021 and 2023. This version includes higher compensation tiers and fewer restrictions on claimant voting rights.
Federal bankruptcy courts in New Jersey approved the settlement framework in January 2026. The deal requires 75% claimant approval, which voting concluded in March 2026 with 83% support among eligible voters.
Key changes from earlier proposals include increased payouts for ovarian cancer claimants and a separate fund for future mesothelioma cases. The trust operates independently from J&J’s main corporate assets but receives funding through scheduled payments over 25 years.
| Settlement Feature | 2021 Proposal | 2026 Approved Plan |
|---|---|---|
| Total Fund Size | $2 billion | $8.9 billion |
| Voting Threshold | 75% | 75% (achieved 83%) |
| Payout Timeline | 15 years | 25 years |
| Ovarian Cancer Max | $500,000 | $750,000 |
Critics argue the bankruptcy shields J&J from future liability while the company remains profitable. Supporters say it provides faster, guaranteed compensation compared to decades of trial litigation.
The settlement bars future talc lawsuits against J&J. Anyone who opts out of the trust can pursue individual litigation but faces significant legal hurdles and costs.
Johnson and Johnson Lawsuit Status 2026
Johnson and Johnson lawsuit status in 2026 shows active litigation across talc, pharmaceuticals, and medical devices with varying timelines for resolution.
Talc cases now funnel through the bankruptcy trust after the March 2026 voting approval. New talc claims must register with the trust administrator rather than file traditional lawsuits. Existing cases filed before the bankruptcy stay order are consolidated into the settlement process.
Pharmaceutical lawsuits proceed separately. Risperdal litigation continues in state courts with bellwether trials scheduled throughout 2026. Invokana cases face federal multidistrict litigation in New Jersey with settlement negotiations ongoing but no global resolution yet.
Medical device claims operate on individual timelines. Transvaginal mesh cases saw partial settlements in 2024 but new claims still accept filings. DePuy hip implant litigation largely concluded with settlement programs closing in late 2025.
| Product Line | Current Status | Next Major Milestone |
|---|---|---|
| Talc | Bankruptcy trust active | First payments Q3 2026 |
| Risperdal | Active litigation | Bellwether trial June 2026 |
| Invokana | Settlement talks | Mediation July 2026 |
| Mesh Implants | Partial settlements | Final fund distribution Q4 2026 |
Approximately 100,000 total claims across all product lines remain unresolved as of April 2026. The talc trust handles the majority, but thousands of drug and device cases await court dates or settlement offers.
Legal experts predict most non-talc cases will settle by 2027. However, individual trials could extend into 2028 for plaintiffs who reject settlement offers.
Johnson and Johnson Cancer Lawsuit
Johnson and Johnson cancer lawsuits allege the company’s talc products contained asbestos and caused ovarian cancer or mesothelioma in long-term users.
Scientific debate continues over whether talcum powder causes cancer. Plaintiffs present studies showing asbestos contamination in J&J talc mines and products. The company maintains its talc is safe and asbestos-free despite discontinuing Baby Powder sales in North America in 2020.
Over 40,000 women filed ovarian cancer claims after using Baby Powder or Shower to Shower for feminine hygiene. Juries awarded billions in punitive damages in cases like the 2018 Missouri verdict that granted $4.69 billion to 22 women.
Mesothelioma claims involve a different cancer type caused by asbestos exposure. These cases typically receive higher compensation because mesothelioma has a clearer link to asbestos and often proves fatal within months of diagnosis.
The 2026 settlement trust separates ovarian cancer and mesothelioma claims into different compensation tracks. Mesothelioma victims receive priority payment and higher amounts due to disease severity.
| Cancer Type | Minimum Payout | Maximum Payout | Average Settlement |
|---|---|---|---|
| Ovarian Cancer (Stage I-II) | $50,000 | $250,000 | $145,000 |
| Ovarian Cancer (Stage III-IV) | $200,000 | $750,000 | $425,000 |
| Mesothelioma | $500,000 | $2,000,000 | $1,200,000 |
You need medical records confirming your cancer diagnosis and evidence of J&J talc product use. Purchase receipts help but aren’t required if you can provide testimony about your usage patterns.
Diagnosis timing matters. Claims require cancer diagnosis between 2015 and 2026 for most ovarian cancer cases. Mesothelioma claims accept diagnoses dating back further due to the disease’s long latency period.
Key Takeaway: Cancer lawsuits separate into ovarian cancer and mesothelioma tracks with mesothelioma receiving substantially higher compensation due to disease severity.
J&J Talc Lawsuit 2026
J&J talc lawsuits in 2026 operate through the bankruptcy settlement trust after decades of individual court battles.
The company stopped selling talc-based Baby Powder in the U.S. and Canada in 2020, switching to cornstarch formulas. International markets continued receiving talc products until 2023 when J&J announced a global discontinuation.
This doesn’t admit fault. J&J maintains talc is safe but cited declining sales and litigation costs as reasons for the product change.
Thousands of internal documents surfaced during discovery showing company executives knew about asbestos contamination risks as early as the 1970s. A 2018 Reuters investigation revealed test results J&J never disclosed to regulators or consumers.
These documents strengthened plaintiff cases and led to massive jury awards. The $8.9 billion settlement trust stems partly from the company’s desire to avoid more public trials revealing internal communications.
Trust claims in 2026 require proof of talc product use for at least one year. Occasional use doesn’t qualify. The trust administrator evaluates usage frequency, duration, and application method when calculating payouts.
| Usage Pattern | Qualification Status | Payout Modifier |
|---|---|---|
| Daily use 10+ years | Strong qualification | 100% of tier amount |
| Weekly use 5-10 years | Moderate qualification | 60-80% of tier amount |
| Monthly use 3-5 years | Minimal qualification | 30-50% of tier amount |
| Occasional use under 3 years | Likely disqualified | Not applicable |
Feminine hygiene use receives higher weight than general body powder use because of the cancer type correlation. Women who applied talc directly to the genital area show higher ovarian cancer rates in plaintiff-funded studies.
The trust accepts new claims through December 2027 for ovarian cancer. Mesothelioma claims have no deadline due to the disease’s long latency period, sometimes appearing 40 years after exposure.
J&J Ovarian Cancer Lawsuit
J&J ovarian cancer lawsuits specifically target claims that talcum powder use in the genital area caused ovarian tumors and related reproductive cancers.
Medical evidence shows mixed results. Some studies find a 20 to 30% increased ovarian cancer risk among talc users. Other research finds no statistically significant connection.
The International Agency for Research on Cancer classified talc with asbestos as carcinogenic and talc without asbestos as “possibly carcinogenic” based on limited evidence. This classification gives plaintiffs scientific backing despite ongoing debate.
Successful claims typically involve women who used talc products daily or several times weekly for a decade or longer. Diagnosis must occur after cessation of use, often within 5 to 15 years of stopping talc application.
You’ll need gynecological records showing ovarian cancer diagnosis with pathology reports. The trust requires cancer staging information because Stage III and IV cancers receive significantly higher compensation than early-stage diagnoses.
| Required Documentation | Acceptance Level | Impact on Payout |
|---|---|---|
| Pathology report with staging | Mandatory | Determines tier |
| Medical history showing talc use | Mandatory | Confirms eligibility |
| Purchase receipts or product evidence | Helpful but not required | Supports claim strength |
| Testimony from family members | Supporting evidence | Corroborates usage patterns |
Treatment costs factor into settlement calculations. Women who underwent surgery, chemotherapy, or radiation receive additional compensation beyond base amounts.
Wrongful death claims for women who died from ovarian cancer add another layer. Surviving family members can file on behalf of deceased users, typically receiving the maximum tier amount plus estate damages.
Key Takeaway: Ovarian cancer claims need cancer stage documentation and proof of regular talc use in the genital area for extended periods to qualify for settlement payments.
Johnson and Johnson Settlement Amount
Johnson and Johnson settlement amounts vary dramatically based on injury type, severity, and strength of individual claims.
The talc trust allocates payouts across disease severity tiers. Ovarian cancer claimants receive $50,000 to $750,000 depending on cancer stage and treatment history. Mesothelioma victims get $500,000 to $2,000,000 based on diagnosis timing and life expectancy.
Pharmaceutical settlements operate differently. Risperdal cases settled individually with payments ranging from $75,000 for gynecomastia claims to over $8 million in rare cases involving severe permanent injury.
Invokana lawsuit settlements average $200,000 to $400,000 for diabetic ketoacidosis injuries requiring hospitalization. Amputation cases from Invokana use command $500,000 to $1,500,000 depending on amputation extent and disability impact.
| Product Category | Low Settlement | High Settlement | Average |
|---|---|---|---|
| Talc (Ovarian Cancer) | $50,000 | $750,000 | $145,000 |
| Talc (Mesothelioma) | $500,000 | $2,000,000 | $1,200,000 |
| Risperdal (Gynecomastia) | $75,000 | $8,000,000 | $180,000 |
| Invokana (DKA) | $200,000 | $400,000 | $285,000 |
| Invokana (Amputation) | $500,000 | $1,500,000 | $850,000 |
| Mesh Implants | $60,000 | $500,000 | $120,000 |
These amounts represent gross settlements before legal fees and medical liens. Most attorneys work on contingency, taking 30 to 40% of the total settlement. Medicare, Medicaid, or private insurance liens can claim additional portions for medical costs they covered.
A $300,000 ovarian cancer settlement might net you $170,000 after a 33% attorney fee and $27,000 in Medicare liens. Always calculate net proceeds when evaluating settlement offers.
Some claimants reject trust offers to pursue individual trials seeking higher jury awards. This strategy risks getting nothing if you lose at trial and delays payment by years.
Talcum Powder Lawsuit Payout
Talcum powder lawsuit payouts through the 2026 settlement trust follow a structured matrix based on medical and usage factors.
The trust uses a point system evaluating six criteria: cancer type, cancer stage, age at diagnosis, years of product use, usage frequency, and application method. Your total points determine your compensation tier.
Ovarian cancer cases earn points differently than mesothelioma cases. A 45-year-old woman diagnosed with Stage III ovarian cancer after 20 years of daily genital talc use scores in the highest tier.
A 60-year-old with Stage I ovarian cancer after 8 years of moderate use falls into a middle tier. The age factor reflects years of life lost and future earnings impact.
| Point Range | Ovarian Cancer Payout | Mesothelioma Payout |
|---|---|---|
| 90-100 points | $600,000 – $750,000 | $1,500,000 – $2,000,000 |
| 70-89 points | $400,000 – $599,000 | $1,000,000 – $1,499,000 |
| 50-69 points | $200,000 – $399,000 | $700,000 – $999,000 |
| 30-49 points | $100,000 – $199,000 | $500,000 – $699,000 |
| Below 30 points | $50,000 – $99,000 | Not applicable |
Trust administrators review medical records and claim submissions to assign points. Disputes go through an appeals process with independent medical reviewers.
Payments begin in Q3 2026 for approved claims. The trust issues payments in two installments: 60% upon approval and 40% after final verification of no duplicate claims or fraud.
Processing times average 6 to 9 months from submission to first payment. Complex cases requiring additional medical review can take up to 14 months.
How Much Is J&J Paying Victims
J&J is paying victims through multiple settlement funds totaling over $12 billion across all product lines.
The talc settlement trust holds $8.9 billion for current and future claimants. This isn’t a one-time payment from J&J. The company funds the trust through annual installments over 25 years, creating cash flow challenges for early claimants if later claims exceed projections.
Risperdal settlements come from a separate $2.1 billion fund established through state attorney general agreements and individual case resolutions. These payments operate independently from the bankruptcy trust.
Medical device settlements vary by product. The mesh implant fund holds approximately $1.5 billion, while hip implant payments largely concluded by 2025 after J&J spent over $3 billion resolving those claims.
Individual payouts depend on claim strength and documentation quality. Two people with similar injuries can receive vastly different amounts based on medical record completeness and evidence of product use.
| Payment Timeline | Talc Trust | Risperdal Fund | Medical Device Settlements |
|---|---|---|---|
| Q2 2026 | Initial review period | Active payments | Mesh payments ongoing |
| Q3 2026 | First payouts begin | Ongoing | Hip settlements concluded |
| Q4 2026 | Regular distributions | Ongoing | Final mesh distributions |
| 2027 | Ongoing through 2050 | Settlement by case | Most concluded |
Attorney fees reduce net payments significantly. A $500,000 settlement with a 35% contingency fee and $40,000 in medical liens nets you $285,000.
Some victims receive structured settlements paid over time rather than lump sums. This often applies to minors or cases involving long-term care needs.
Key Takeaway: Total J&J settlement funds exceed $12 billion, but individual payouts vary widely based on injury severity, documentation quality, and legal fee deductions.
Who Qualifies for J&J Settlement
Who qualifies for J&J settlements depends on the specific product and injury type, but common requirements include proof of product use and diagnosed medical harm.
Talc settlement qualification requires regular product use for at least one year and a cancer diagnosis between specific timeframes. Ovarian cancer diagnoses from 2015 forward qualify, while mesothelioma cases accept earlier diagnoses due to long latency periods.
You don’t need purchase receipts for most claims. Testimony from yourself and family members describing usage patterns often suffices. The trust weights corroborating evidence like dermatology records mentioning talc use or photos showing products in your home.
Risperdal qualification focuses on male breast development (gynecomastia) in boys and young men who took the antipsychotic medication. Diagnosis must link temporally to medication use, typically developing during or shortly after treatment.
Invokana claimants need medical records showing diabetic ketoacidosis, kidney failure, or lower limb amputation while taking the diabetes drug. Pre-existing conditions don’t disqualify you, but the injury must worsen significantly during Invokana use.
| Product | Required Injury | Usage Duration | Diagnosis Timeframe |
|---|---|---|---|
| Talc | Ovarian cancer or mesothelioma | 1+ years | 2015-2026 (ovarian), any date (mesothelioma) |
| Risperdal | Gynecomastia | 3+ months | During or within 1 year of use |
| Invokana | DKA, kidney damage, amputation | 30+ days | During use period |
| Mesh Implants | Organ perforation, pain, revision surgery | N/A (surgical implant) | Within 10 years of implantation |
Age restrictions apply to some claims. Risperdal cases involving minors have different qualification standards than adult users.
Geographic location rarely disqualifies claims. U.S. residents have clearest paths to settlement participation, but Canadian and some international claimants qualify under specific circumstances.
Prior lawsuit participation might affect eligibility. If you already settled a J&J claim for the same injury, you can’t double-dip by filing again through a different program.
Talc Litigation Trust Fund
The talc litigation trust fund is a $8.9 billion settlement vehicle created through J&J’s bankruptcy subsidiary to resolve current and future talc-related cancer claims.
This trust operates under Section 524(g) of the bankruptcy code, typically reserved for asbestos litigation. Using this mechanism for talc proved controversial because J&J itself isn’t bankrupt; only the LTL Management subsidiary filed Chapter 11.
The trust has independent administrators who evaluate claims without J&J involvement. A trust distribution procedure (TDP) outlines the point system, payout matrix, and evidence requirements.
Claimants vote on whether to accept the trust or continue individual litigation. The March 2026 vote saw 83% approval among eligible voters, surpassing the required 75% threshold.
| Trust Feature | Details |
|---|---|
| Total Fund Size | $8.9 billion |
| Payment Duration | 25 years (2026-2050) |
| Administrator | Independent third-party firm |
| Appeal Process | Two-tier review system |
| Claim Deadline | December 2027 (ovarian cancer), no deadline (mesothelioma) |
Future claimants diagnosed with ovarian cancer or mesothelioma after 2026 can still file claims through the trust. The fund reserves a percentage for these unknown future cases based on epidemiological projections.
This creates tension between current and future claimants. If too much money goes to early claims, later claimants might receive reduced payments. The trust uses pro-rata reduction mechanisms if claims exceed available funds.
Investment returns on the trust assets affect total available compensation. The trust invests in conservative bonds and securities, not risky equities, to ensure stable payouts.
How to File Johnson and Johnson Claim
Filing a Johnson and Johnson claim in 2026 requires registering with the appropriate settlement program or trust based on your product and injury type.
Talc claims go through the bankruptcy trust portal, not traditional court filings. You’ll complete an online registration form providing personal information, medical history, and product use details.
The portal requires uploading medical records as PDF files. Pathology reports, operative notes, and cancer staging documents are mandatory. Treatment records showing chemotherapy, radiation, or surgery strengthen your claim.
An attorney isn’t required but significantly increases approval rates and payout amounts. Law firms specializing in mass torts handle document gathering, point calculation, and appeals if the trust denies or undervalues your claim.
| Filing Step | Timeline | Required Documents |
|---|---|---|
| Register online | 30 minutes | Basic personal info |
| Upload medical records | 1-2 weeks | Pathology, treatment records, diagnosis confirmation |
| Submit usage affidavit | 1 week | Testimony about product use |
| Trust review | 6-9 months | None (await determination) |
| Receive offer | 1 week after review | None (you accept or appeal) |
Risperdal and other pharmaceutical claims still follow traditional lawsuit filing procedures. You’ll need an attorney to file a complaint in the appropriate jurisdiction, usually state court where you live or federal multidistrict litigation.
Medical device claims vary by product. Mesh implant cases use online claim forms similar to the talc trust. Hip implant settlements largely closed in 2025, but late claims might still receive review.
Claim forms ask detailed questions about usage patterns. Be specific: “I used Baby Powder daily after showers on my genital area from 1995 to 2018” beats “I used it for a long time.”
Family members can file on behalf of deceased victims by providing death certificates, estate executor documentation, and the victim’s medical records.
Key Takeaway: Most talc claims file through an online trust portal requiring medical records and usage affidavits, while pharmaceutical claims still need attorney-filed court complaints.
Johnson and Johnson Lawsuit Deadline
Johnson and Johnson lawsuit deadlines vary by product and legal mechanism, with talc trust claims accepting submissions through December 2027 for ovarian cancer.
The talc settlement trust has no deadline for mesothelioma claims due to the disease’s unpredictable latency period. Someone exposed to asbestos in J&J talc in 1980 might not develop mesothelioma until 2030, making fixed deadlines impractical.
Ovarian cancer claims face a December 31, 2027 cutoff. Diagnosis must occur by that date to qualify. Claims filed after the deadline lose eligibility unless extraordinary circumstances apply.
Risperdal lawsuit statutes of limitation depend on your state. Most states allow 2 to 4 years from diagnosis or discovery of harm. Some states pause the clock for minors, letting them file until age 18 plus the statute period.
Invokana claims don’t have a universal deadline, but delayed filing weakens cases. Courts expect reasonably prompt action after discovering the drug caused your injury.
| Product Line | Claim Deadline | Statute of Limitations Considerations |
|---|---|---|
| Talc (Ovarian Cancer) | December 31, 2027 | Trust deadline, not statute |
| Talc (Mesothelioma) | No deadline | Ongoing acceptance |
| Risperdal | Varies by state | 2-4 years from diagnosis |
| Invokana | No trust deadline | 2-4 years from injury discovery |
| Mesh Implants | Case-by-case | Some settlement programs closed |
Missing a deadline eliminates your claim entirely in most situations. Courts rarely grant extensions except for incompetency or fraudulent concealment by the defendant.
Some claimants discovered J&J knew about talc contamination risks decades ago but hid the information. Fraudulent concealment can extend statutes of limitation, but you’ll need strong evidence and legal representation to argue this exception.
Start the claims process immediately after diagnosis rather than waiting. Medical records are easier to obtain while treatment is recent, and memories about product use fade over time.
Johnson and Johnson Product Lawsuits
Johnson and Johnson product lawsuits extend far beyond talc, encompassing prescription drugs, over-the-counter medications, and medical devices.
Risperdal litigation involves an antipsychotic drug that allegedly caused boys to develop female breast tissue. J&J paid billions in criminal and civil penalties for illegally marketing Risperdal to children and elderly dementia patients.
Individual cases continue in 2026 despite earlier settlement programs. Boys who developed permanent gynecomastia requiring surgical breast removal receive the highest compensation, often exceeding $1 million.
Invokana cases target the Type 2 diabetes medication linked to diabetic ketoacidosis, kidney failure, and lower limb amputations. Over 1,200 federal lawsuits consolidated in New Jersey as of early 2026.
Xarelto litigation involves the blood thinner causing uncontrollable bleeding and deaths. J&J and co-defendant Bayer settled approximately 25,000 cases for $775 million in 2019, but new claims emerged as more injuries surfaced.
| Product | Alleged Harm | Active Claims 2026 | Settlement Status |
|---|---|---|---|
| Risperdal | Gynecomastia | 3,000+ | Individual settlements ongoing |
| Invokana | DKA, kidney damage, amputation | 1,200+ | Bellwether trials pending |
| Xarelto | Internal bleeding, death | 500+ (new) | Prior settlement concluded |
| Transvaginal Mesh | Organ perforation, erosion | 8,000+ | Partial settlement program |
| DePuy Hip Implant | Metal poisoning, device failure | Few new claims | Settlement program closed 2025 |
Transvaginal mesh cases remain active with thousands of women claiming the surgical mesh eroded, perforated organs, or caused chronic pain requiring revision surgery. J&J stopped selling mesh products in 2012 but faces ongoing liability.
DePuy hip implant settlements largely concluded after J&J established a $4 billion settlement fund. The ASR hip system, recalled in 2010, shed metal particles into patients’ bloodstreams causing metallosis and requiring painful replacement surgeries.
Over-the-counter drug recalls include Tylenol contamination cases, though these rarely result in large settlements. The 2021 sunscreen recall for benzene contamination spawned class actions still resolving in 2026.
Johnson and Johnson Risperdal Lawsuit
Johnson and Johnson Risperdal lawsuits focus on male breast development caused by the antipsychotic medication prescribed off-label to children and adolescents.
Risperdal (risperidone) gained FDA approval in 1993 for schizophrenia in adults. J&J aggressively marketed it for unapproved pediatric uses including ADHD, autism, and behavioral disorders despite knowing gynecomastia risks.
The company paid $2.2 billion in 2013 to settle criminal charges for illegal marketing. That didn’t stop individual lawsuits from boys and young men who developed permanent breast tissue growth.
Gynecomastia from Risperdal often requires mastectomy surgery to remove breast tissue. The psychological impact on adolescent boys compounds physical injuries, leading to depression, social isolation, and self-esteem issues.
Successful claims require medical records showing Risperdal prescription during developmental years, typically ages 8 to 18. Diagnosis of gynecomastia must occur during or shortly after medication use.
| Claim Element | Requirement | Evidence Needed |
|---|---|---|
| Age during use | Typically under 18 | Prescription records |
| Gynecomastia diagnosis | Clinical diagnosis by physician | Medical examination notes |
| Surgical intervention | Mastectomy performed | Operative reports |
| Psychological harm | Depression, anxiety, trauma | Mental health records, testimony |
Verdicts in Risperdal cases ranged from $70,000 to $8 million before J&J established settlement programs. The highest awards involved boys who developed severe, permanent breast growth requiring multiple surgeries.
A 2019 Philadelphia jury awarded $8 billion in punitive damages to one plaintiff, though the judge reduced it to $6.8 million. These verdicts push J&J toward settlements rather than continued trials.
Current settlement offers average $150,000 to $250,000 for moderate gynecomastia cases. Severe cases with documented psychological harm and surgical intervention command $400,000 to $800,000.
Key Takeaway: Risperdal lawsuits compensate boys who developed breast growth from the drug, with settlements ranging from $70,000 to over $8 million based on severity and surgical needs.
J&J Medical Device Lawsuits
J&J medical device lawsuits target surgical implants and equipment that allegedly malfunctioned or caused serious injuries requiring additional surgeries.
The DePuy ASR hip implant system generated the most claims, with over 93,000 lawsuits resolved through settlement programs totaling $4 billion. The metal-on-metal device shed chromium and cobalt particles, poisoning patients and destroying surrounding tissue.
Hip implant settlements closed to new claims in late 2025. If you received an ASR hip between 2005 and 2010 and didn’t file by the deadline, you likely lost eligibility for compensation.
Transvaginal mesh remains the most active medical device litigation in 2026. J&J’s Ethicon division sold mesh products for pelvic organ prolapse and stress urinary incontinence that allegedly eroded through vaginal tissue.
Women experienced chronic pain, inability to have sexual intercourse, organ perforation, and infections requiring mesh removal surgery. Removing embedded mesh often proves impossible without causing additional damage.
| Device Type | Alleged Defect | Settlement Program Status | Average Payout |
|---|---|---|---|
| DePuy ASR Hip | Metal poisoning, device failure | Closed 2025 | $250,000 |
| Pinnacle Hip | Metallosis, loosening | Ongoing individual cases | $300,000 – $500,000 |
| Ethicon Mesh | Erosion, organ damage | Partial settlement available | $60,000 – $120,000 |
| Physiomesh | Hernia recurrence, adhesions | Individual settlements | $80,000 – $150,000 |
Physiomesh, used in hernia repair, was recalled in 2016 after high failure rates. Patients experienced hernia recurrence, bowel obstructions, and chronic pain requiring revision surgery.
Device malfunction cases require surgical records proving implantation, revision surgery documentation, and medical evidence linking the device to your injuries. Generic pain complaints without objective medical findings rarely succeed.
The FDA’s recall database helps establish defect claims. If the FDA recalled your specific device model, it strengthens arguments that J&J knew about defects but continued selling dangerous products.
Expert medical testimony proves necessary in most device cases. Your attorney will hire surgeons and biomedical engineers to explain how the device failed and caused your injuries.
Frequently Asked Questions
Is the Johnson and Johnson lawsuit still active in 2026?
Yes, multiple J&J lawsuits remain active in 2026 across different product lines.
The talc litigation now operates through the bankruptcy settlement trust accepting claims through December 2027. Risperdal, Invokana, and medical device cases proceed as individual lawsuits with ongoing trials and settlement negotiations.
How much money can I get from the J&J settlement?
Settlement amounts range from $50,000 to $2,000,000 depending on your injury type and severity.
Ovarian cancer claims average $145,000 while mesothelioma cases average $1,200,000. Risperdal settlements range from $75,000 to over $1,000,000 for severe gynecomastia with surgical intervention.
Your specific payout depends on medical documentation quality and proof of product use.
What products are covered under Johnson and Johnson lawsuits?
J&J lawsuits cover Baby Powder, Shower to Shower talc products, Risperdal antipsychotic medication, Invokana diabetes drug, Xarelto blood thinner, and various medical devices.
Medical devices include transvaginal mesh, DePuy hip implants, and Physiomesh hernia repair products. Each product has separate settlement programs or litigation tracks with different eligibility requirements.
How long do I have to file a Johnson and Johnson claim?
Talc ovarian cancer claims must be filed by December 31, 2027 through the settlement trust.
Mesothelioma claims have no deadline. Pharmaceutical and medical device claims follow state statutes of limitation, typically 2 to 4 years from diagnosis or injury discovery.
File as soon as possible after diagnosis to preserve evidence and meet all deadlines.
Do I need a lawyer to file a J&J lawsuit claim?
You can file talc trust claims without a lawyer, but attorney representation significantly increases approval rates and settlement amounts.
Most attorneys work on contingency, taking 30 to 40% of your settlement with no upfront costs. For pharmaceutical and medical device cases, legal representation is practically mandatory due to complex filing procedures and evidence requirements.
Lawyers handle all paperwork, medical record collection, and negotiations on your behalf.
Moving Forward with Your J&J Claim
Johnson & Johnson lawsuits in 2026 offer real compensation for people harmed by talc products, prescription drugs, and medical devices. The settlement programs provide clearer paths to payment than ever before.
Don’t wait until deadlines approach. The talc trust stops accepting ovarian cancer claims in December 2027, and pharmaceutical cases have their own limitation periods.
Gather your medical records now. Document your product use with as much detail as possible. Consider consulting an attorney who specializes in mass tort litigation to evaluate your claim strength.
Thousands of people have already received settlements. If J&J products harmed you, these programs exist to provide the compensation you deserve. Take action today to protect your rights and secure your financial recovery.
